TCG Crossover Management LLC Has $56.35 Million Position in Xencor, Inc. (NASDAQ:XNCR)

TCG Crossover Management LLC lifted its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 1.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,452,138 shares of the biopharmaceutical company's stock after purchasing an additional 25,000 shares during the quarter. Xencor comprises approximately 5.5% of TCG Crossover Management LLC's holdings, making the stock its 3rd largest position. TCG Crossover Management LLC owned 3.50% of Xencor worth $56,350,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in XNCR. Finepoint Capital LP purchased a new stake in Xencor during the 4th quarter valued at $15,167,000. Vanguard Group Inc. lifted its holdings in shares of Xencor by 5.5% during the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after purchasing an additional 418,040 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Xencor by 21.3% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock valued at $25,102,000 after buying an additional 192,080 shares during the last quarter. Geode Capital Management LLC increased its holdings in Xencor by 12.3% in the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock worth $37,578,000 after buying an additional 179,526 shares in the last quarter. Finally, Barclays PLC raised its position in Xencor by 112.6% in the 4th quarter. Barclays PLC now owns 330,745 shares of the biopharmaceutical company's stock worth $7,600,000 after buying an additional 175,177 shares during the last quarter.

Wall Street Analysts Forecast Growth

XNCR has been the subject of a number of research analyst reports. StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Wedbush reissued an "outperform" rating and set a $31.00 price target on shares of Xencor in a report on Wednesday. Finally, William Blair assumed coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and an average price target of $32.86.

Xencor Stock Performance

Shares of NASDAQ:XNCR traded up $0.40 during midday trading on Friday, hitting $11.26. The company had a trading volume of 1,057,567 shares, compared to its average volume of 621,441. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24. The company has a fifty day moving average of $11.31 and a two-hundred day moving average of $18.07. The company has a market cap of $801.17 million, a price-to-earnings ratio of -3.52 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.